Description

EACH LUCISOT TABLET CONTAINS: 

Sotorasib ……………… 120mg

INDICATION:  

LuciSot is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

DOSAGE AND USE:

The recommended dosage of LuciSot is 960 mg (eight 120 mg tablets) orally once daily until disease progression or unacceptable toxicity. Take LuciSot at the same time each day with or without food.

Recommended LuciSot Dose Reduction Levels for Adverse Reactions:

1. First dose reduction: 480 mg (4 tablets) once daily

2. Second dose reduction: 240 mg (2 tablets) once daily

Tablets should be swallowed whole & not chewed or crushed.

STORAGE: 

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Keep medicine out of the reach of Children.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING AND PRECAUTION: